Table 2.1. Incidence and Prevalence of Selected Cancers in the United States, 2006

Table 2.2. Five-Year Relative Survival Rates by Stage of Diagnosis for Major Cancers Targeted by Immunotherapies and Cancer Vaccines, 1995–2001

Table 3.1. Selected Chemotherapy Drugs Approved by the FDA for Treatment of Cancer

Table 3.2. Selected Drugs Approved by the FDA for Treatment of Breast Cancer

Table 3.3. Selected Drugs Approved by the FDA for Treatment of Colorectal Cancer

Table 3.4. Selected Drugs Approved by the FDA for Treatment of Lung Cancer

Table 3.5. Selected Drugs Approved by the FDA for Treatment of Non–Hodgkin’s Lymphoma (NHL)

Table 3.6. Selected Drugs Approved by the FDA for Treatment of Melanoma

Table 3.7. Selected Drugs Approved by the FDA for Treatment of Advanced or Metastatic Pancreatic Cancer

Table 3.8. Selected Drugs Approved by the FDA for Treatment of Prostate Cancer

Table 3.9. Selected Drugs Approved by the FDA for Treatment of Advanced or Metastatic Renal Cell Carcinoma

Table 4.1. Selected Examples of Clinical Programs in Cancer Immunotherapies and Vaccines That Have Been Discontinued or Suspended

Table 4.2. Cancer Immunotherapies and Vaccines in Clinical Trials for Treatment of Breast Cancer

Table 4.3. Cancer Immunotherapies and Vaccines in Clinical Trials for Treatment of Colorectal Cancer

Table 4.4. Cancer Immunotherapies and Vaccines in Clinical Trials for Treatment of Lung Cancer

Table 4.5. Cancer Immunotherapies and Vaccines in Clinical Trials for Treatment of Non–Hodgkin’s Lymphoma

Table 4.6. Cancer Immunotherapies and Vaccines in Clinical Trials for Treatment of Melanoma

Table 4.7. Cancer Immunotherapies and Vaccines in Clinical Trials for Treatment of Pancreatic Cancer

Table 4.8. Cancer Immunotherapies and Vaccines in Clinical Trials for Treatment of Prostate Cancer

Table 4.9. Cancer Immunotherapies and Vaccines in Clinical Trials for Treatment of Renal Cell Carcinoma

Figure 4.1. SWOT Analysis for PF-3512676 Compared with Standard Therapy for Treatment of Non-Small Cell Lung Cancer

Figure 4.2. SWOT Analysis for BiovaxID Compared with Standard Therapy for Treatment of Follicular Non–Hodgkin’s Lymphoma (NHL)

Figure 4.3. SWOT Analysis for FavId Compared with Standard Therapy for Treatment of Low-Grade, Follicular Non–Hodgkin's Lymphoma

Figure 4.4. SWOT Analysis for MyVax Personalized Immunotherapy Compared with Standard Therapy for Treatment of Follicular Non–Hodgkin's Lymphoma (NHL)

Figure 4.5. SWOT Analysis for Oncophage Compared with Standard Therapy for Metastatic Melanoma

Figure 4.6. SWOT Analysis for Ipilimumab (MDX-010) Compared with Standard Therapy for Treatment of Metastatic Melanoma

Figure 4.7. SWOT Analysis for Ticilimumab (CP-675,206) Compared with Standard Therapy for Treatment of Metastatic Melanoma

Figure 4.8. SWOT Analysis for Virulizin Compared with Standard Therapy for Treatment of Pancreatic Cancer

Figure 4.9. SWOT Analysis for GV001 Compared with Standard Therapy for Treatment of Pancreatic Cancer

Figure 4.10. SWOT Analysis for Insegia Compared with Standard Therapy for Treatment of Pancreatic Cancer

Figure 4.11. SWOT Analysis for Provenge Compared with Standard Therapy for Treatment of Prostate Cancer

Figure 4.12. SWOT Analysis for DCVax-Prostate Compared with Standard Therapy for Treatment of Prostate Cancer

Figure 4.13. SWOT Analysis for Oncophage Compared with Standard Therapy for Renal Cell Carcinoma (RCC)